Person:
DOĞANAY, ÖZGE

Profile Picture
Status
Organizational Units
OrgUnit Logo
Organizational Unit
Job Title
First Name
ÖZGE
Last Name
DOĞANAY
Name
Email Address
Birth Date

Filters

2019 - 201912020 - 20222
Reset filters

Settings

Has files: true ×

Search Results

Now showing 1 - 3 of 3
  • Thumbnail Image
    PublicationOpen Access
    Precautions Prior to the Treatment in Oraland Maxillofacia Surgery in the Reopening Period during COVID-19 Pandemic
    (2021-02-01T00:00:00Z) DOĞANAY, Özge; DOLANMAZ, DOĞAN; DOĞANAY, ÖZGE; DOLANMAZ, DOĞAN
    Oral and maxillofacial surgery is correlated with a high risk of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) transmission. To assist our colleagues under physical and psychological burden by using the current literature data and considering the recommendations of the Ministry of Health Science board decisions, -The American Association of Oral and Maxillofacial Surgeons, American Dental Association and Centers for Disease Control and Prevention, this literature review has been prepared in order to organize elective surgeries. Interventions should be planned after evaluating both the logistic conditions of the institution and the situation during the pandemic before per forming elective surgery. In order to save resources and to avoid unnecessary exposure to infected patients, there is the need to schedule interventions depending on their priority, In general, Emergency procedures do not allow any delay. In elective surgeries, risk assessments of both the patient and the surgical procedure is left to the surgeon. Inpatient and outpatient units have to he organized in such a way that the risk of cross-infection among patients is reduced to a minimum. Active Coronavirus disease-19 (COVID-19) patients should he treated in the operating room with negative pressure, and aerosol formation must be reduced to a minimum, During reopening period, treatments may he applied in cans whew appropriate conditions arc provided and recommendations for patient and physician safety are taken.
  • Thumbnail Image
    PublicationOpen Access
    Multifocal, Non-Human Papillomavirus Inflammatory Papillary Hyperplasia: A Rare Case Report
    (2022-01-01T00:00:00Z) DOĞANAY, ÖZGE; AKTAŞ, TAHA; DOLANMAZ, DOĞAN; KIRAN, Tuğçe; DOĞANAY, ÖZGE; AKTAŞ, TAHA; DOLANMAZ, DOĞAN; KIRAN, TUĞÇE
    Oral papillary lesions include a variety of reactive, developmental, and neoplastic conditions. Inflammatory papillary lesions almost involve the hard palate and are usually associated with the use of ill-fitting dentures and poor oral hygiene. Contrarily, perioral involvement of papillomatosis can also be found in neoplastic or syndromic conditions. This case report aimed to present a 44-yearold male patient with rarely encountered multifocal non-human papillomavirus (HPV) inflammatory papillary hyperplasia and evaluate the differential diagnosis that represents similar clinical and histopathological conditions. Multifocal papillary lesions on the lips, tongue, alveolar crest, and oral mucosa were surgically removed via scalpel and laser application. The histopathologic examination confirmed the diagnosis of non-HPV inflammatory papillary hyperplasia. Complete recovery was achieved and the patient was rehabilitated with a new removable prosthesis. Surgical removal of the papillary lesions seems to be a reliable treatment option. In addition to HPV-induced lesions and poor oral hygiene, other etiologic factors should be eliminated with clinicopathologic consultation and genetic investigations.
  • Thumbnail Image
    PublicationOpen Access
    Management of Patients Using Oral Anticoagulant Agent in Dental Practice
    (2019-01-01) ALKAN, ALPER; YÜCESOY, TÜRKER; DOGANAY, ÖZGE; DOĞANAY, ÖZGE; YÜCESOY, TÜRKER; ALKAN, ALPER
    An increasing number of patients in our country use oral anticoagulants for the prophylaxis and treatment of thromboembolic events. The cornerstone of these groups of agents is warfarin, a vitamin K antagonist, which has been the single alternative used by oral route for several years. However, due to warfarin's late onset and long lasting action and the intense interactions with food and drugs, newer oral anticoagulants have emerged in the market in recent years. Dabigatran, rivaroxaban and apixaban arc the novel agents used in our country. Those drugs should he regulated in the perioperative period when patients receiving oral anticoagulants are referred for dental interventions. The interruption of agents may result in lethal consequences of thromboembolic events, while continuing raises the risk of bleeding. This review outlines the various properties of the oral anticoagulants and the most recent recommendations and guidelines regarding the management of dental patients taking these medications.